Page 41 - Read Online

Page 14 of 14 Irshad et al. Hepatoma Res 2018;4:23 I http://dx.doi.org/10.20517/2394-5079.2018.25

108. Lin W, Choe WH, Hiasa Y, Kamegaya Y, Blackard JT, Schmidt EV, Chung RT. Hepatitis C virus expression suppresses interferon
signaling by degrading STAT1. Gastroenterology 2005;128:1034-41.
109. Lin W, Kim SS, Yeung E, Kamegaya Y, Blackard JT, Kim KA, Holtzman MJ, Chung RT. Hepatitis C virus core protein blocks interferon
signaling by interaction with the STAT1 SH2 domain. J Virol 2006;80:9226-35.
110. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon- inducible protein kinase PKR by HCV E2 protein.
Science 1999;285:107-10.
111. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the
mitochondria to evade innate immunity. Proc Natl Acad Sci U S A 2005;102:17717-22.
112. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardif is an adaptor protein in the RIG-I
antiviral pathway and is targeted by hepatitis C virus. Nature 2005;437:1167-72.
113. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M Jr, Lemon SM. Immune evasion by hepatitis C virus
NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005;102:2992-7.
114. Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M Jr. Control of antiviral
defenses through hepatitis C virus disruption of retinoic acid inducible gene-I signaling. Proc Natl Acad Sci U S A 2005;102:2986-91.
115. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, Gale M Jr. Regulation of interferon regulatory factor-3 by the hepatitis C
virus serine protease. Science 2003;300:1145-8.
116. Xu J, Liu S, Xu Y, Tien P, Gao G. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral
activity of interferon-alpha. Virus Res 2009;141:55-62.
117. Gale MJ Jr, Korth MJ, Katze MG. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism
of interferon resistance. Clin Diagn Virol 1998;10:157-62.
118. Gale MJ Jr, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG. Evidence that hepatitis C
virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology
1997;230:217-27.
119. Gong GZ, Cao J, Jiang YF, Zhou Y, Liu B. Hepatitis C virus non-structural 5A abrogates signal transducer and activator of
transcription-1 nuclear translocation induced by IFN-alpha through dephosphorylation. World J Gastroenterol 2007;13:4080-4.
120. Lan KH, Lan KL, Lee WP, Sheu ML, Chen MY, Lee YL, Yen SH, Chang FY, Lee SD. HCV NS5A inhibits interferon-alpha signaling
through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. J Hepatol 2007;46:759-67.
121. Kumthip K, Maneekarn N. The role of HCV proteins on treatment outcomes. Virol J 2015;12:217.
122. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M,
McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature
2009;461:399-401.
123. Guss D, Sherigar J, Rosen P, Mohanty SR. Diagnosis and management of hepatitis C infection in primary care settings. J Gen Intern
Med 2018;33:551-7.
124. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Sustained
virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84.
125. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL,
Morishima C, Lindsay KL, Lok AS;HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced
chronic hepatitis C. Hepatology 2010;52:833-44.
126. Chen Yi Mei SLG, Thompson AJ, Christensen B, Cunningham G, McDonald L, Bell S, Iser D, Nguyen T, Desmond PV. Sustained
virological response halts fibrosis progression: a long-term follow-up study of people with chronic hepatitis C infection. PLoS One
2017;12:e0185609.
127. Terrault NA, Hassanein TI. Management of the patient with SVR. J Hepatol 2016;65 Suppl 1: S120-9.
128. Ahmed A, Felmlee DJ. Mechanisms of hepatitis C viral resistance to direct acting antivirals. Viruses 2015;7:6716-29.
129. Sesmero E, Thorpe IF. Using the hepatitis C virus RNA-dependent RNA polymerase as a model to understand viral polymerase
structure, function and dynamics. Viruses 2015;7:3974-94.
130. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011;53:1742-51.